ArticleFrontiers in oncology2025
Immune checkpoint inhibitor therapy for advanced HPV-related penile squamous cell carcinoma: a rare case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human papillomavirus type 16 (HPV-16)-associated penile squamous cell carcinoma (PSCC) poses considerable therapeutic challenges, especially in its advanced stages. Although surgery continues to be the cornerstone of treatment, immunotherapeutic approaches hold a promising alternative for patients unable to endure conventional chemotherapy. Case summary: A 69-year-old male presented with progressive ulceration of the foreskin over the course of one year, which ultimately extended to the glans, accompanied by inguinal lymph node metastasis. The patient underwent surgical resection, including bilateral inguinal lymph node dissection. Histopathological examination confirmed a diagnosis of HPV-16-related PSCC with concomitant PD-L1 expression. Given the patient's poor tolerance to chemotherapy, he was treated with four cycles of the PD-1 inhibitor tislelizumab, resulting in a partial response. Conclusion: This case underscores the promising potential of immunotherapy as a viable alternative treatment for advanced PSCC in patients who are unable to tolerate chemotherapy. The synergistic integration of surgical intervention, immunotherapy, and psychological support is essential to achieving the best possible outcomes for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.